{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:43:24Z","timestamp":1792788204251,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jtct.2025.12.947","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:05:48Z","timestamp":1765526748000},"page":"292.e1-292.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS) in CAR-T and TCE-Treated Myeloma and B-Cell Malignancies: Insights from a Pharmacovigilance Study"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3133-5993","authenticated-orcid":false,"given":"Sohaib","family":"Irfan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9642-4961","authenticated-orcid":false,"given":"Fathima Shehnaz","family":"Ayoobkhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7238-1058","authenticated-orcid":false,"given":"Nikhil","family":"Vojjala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raabia","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raeef","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1177-2573","authenticated-orcid":false,"given":"Ishita","family":"Kamboj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al-Ola","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph","family":"McGuirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3168-2521","authenticated-orcid":false,"given":"Zahra","family":"Mahmoudjafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forat","family":"Lutfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jtct.2025.12.947_bib0001","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/16078454.2022.2045724","article-title":"Promising therapeutic approaches for relapsed\/refractory multiple myeloma","volume":"27","author":"Ni","year":"2022","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.947_bib0002","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40164-024-00508-4","article-title":"Novel CAR T-cell therapies for relapsed\/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting","volume":"13","author":"Zhang","year":"2024","journal-title":"Exp Hematol Oncol"},{"issue":"21","key":"10.1016\/j.jtct.2025.12.947_bib0003","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.3390\/cancers15215149","article-title":"Immune effector cell-associated HLH-like syndrome: a review of the literature of an increasingly recognized entity","volume":"15","author":"Fugere","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.jtct.2025.12.947_bib0004","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic Lymphohistiocytosis-Like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2025.12.947_bib0005","unstructured":"Lymphoma Hub. CAR T-cell therapy-associated HLH-like syndrome. 2023. https:\/\/lymphomahub.com\/medical-information\/car-t-cell-therapy-associated-hlh-like-syndrome"},{"issue":"1","key":"10.1016\/j.jtct.2025.12.947_bib0006","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2025.12.947_bib0007","unstructured":"Schuster S, Bishop M, Tam C, et al. Primary analysis of Juliet: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood. 130;Supplement 1:577. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497119810935"},{"issue":"5","key":"10.1016\/j.jtct.2025.12.947_bib0008","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.947_bib0009","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.jtct.2025.12.947_bib0010","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.947_bib0011","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.947_bib0012","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10297","key":"10.1016\/j.jtct.2025.12.947_bib0013","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jtct.2025.12.947_bib0014","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jtct.2025.12.947_bib0015","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.jtct.2025.12.947_bib0016","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.jtct.2025.12.947_bib0017","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1182\/bloodadvances.2021005020","article-title":"Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma","volume":"5","author":"Kennedy","year":"2021","journal-title":"Blood Adv"},{"issue":"15_suppl","key":"10.1016\/j.jtct.2025.12.947_bib0018","doi-asserted-by":"crossref","first-page":"8057","DOI":"10.1200\/JCO.2020.38.15_suppl.8057","article-title":"Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel)","volume":"38","author":"Ahmed","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2025.12.947_bib0019","doi-asserted-by":"crossref","first-page":"E374","DOI":"10.1002\/ajh.26668","article-title":"Hemophagocytic lymphohistiocytosis secondary to CAR-T cells: update from the FDA and Vizient databases","volume":"97","author":"Priyadarshini","year":"2022","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2025.12.947_bib0020","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1182\/blood-2023-185190","article-title":"Immune effector cell-associated hemophagocytic Lymphohistiocytosis-Like syndrome (IEC-HS): a review of pharmacovigilance","volume":"142","author":"Ebinama","year":"2023","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2025.12.947_bib0021","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.3324\/haematol.2022.281455","article-title":"Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy","volume":"108","author":"Song","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jtct.2025.12.947_bib0022","first-page":"1269","article-title":"Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma","volume":"109","author":"Song","year":"2023","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.jtct.2025.12.947_bib0023","first-page":"1784","article-title":"Cilta-cel is associated with improved outcomes and distinct cellular dynamics compared with ide-cel for relapsed or refractory multiple myeloma","volume":"143","author":"Gagelmann","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.12.947_bib0024","article-title":"CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey","volume":"11","author":"Hakan","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"3-4","key":"10.1016\/j.jtct.2025.12.947_bib0025","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-024-01013-w","article-title":"Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy","volume":"46","author":"Hughes","year":"2024","journal-title":"Semin Immunopathol"},{"issue":"20","key":"10.1016\/j.jtct.2025.12.947_bib0026","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2025.12.947_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1396490","article-title":"Mechanisms and management of CAR T toxicity","volume":"14","author":"Ferreri","year":"2024","journal-title":"Front Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725026041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725026041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:10:54Z","timestamp":1774858254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725026041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2666636725026041"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.12.947","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS) in CAR-T and TCE-Treated Myeloma and B-Cell Malignancies: Insights from a Pharmacovigilance Study","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.12.947","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Transplantation and Cellular Therapy. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}